Company intelligence / Profile preview
aptaTargets
Madrid, Madrid, Spainaptatargets.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Successfully completed First-in-Human clinical trial in healthy volunteers (Phase I, NCT04742062) in 2019-2020. Phase Ib portion of a Phase Ib/IIa trial in acute ischemic stroke patients (APRIL study, NCT04734548) was completed in June 2021. Currently advancing to clinical Proof-of-Concept in patients.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Aptamers (single-stranded DNA molecules)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Complutense UniversityRamon y Cajal Hospital
Beyond the preview
Go deeper on aptaTargets.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aptaTargets.